<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Karadimou, A.</style></author><author><style face="normal" font="default" size="100%">Soupos, N.</style></author><author><style face="normal" font="default" size="100%">Sotiropoulou, M.</style></author><author><style face="normal" font="default" size="100%">Zagouri, F.</style></author><author><style face="normal" font="default" size="100%">Haidopoulos, D.</style></author><author><style face="normal" font="default" size="100%">Thomakos, N.</style></author><author><style face="normal" font="default" size="100%">Rodolakis, A.</style></author><author><style face="normal" font="default" size="100%">Antsaklis, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience</style></title><secondary-title><style face="normal" font="default" size="100%">Gynecologic Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Early stage</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognostic factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Serous</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor type</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052578547&amp;doi=10.1016%2fj.ygyno.2011.06.033&amp;partnerID=40&amp;md5=3268f1d63d140cdf464c86fc151b544e</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">123</style></volume><pages><style face="normal" font="default" size="100%">37 - 42</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Objective: Early-stage epithelial ovarian cancer represents a prognostically heterogenous group. We studied prognostic factors in patients treated with adjuvant paclitaxel/carboplatin chemotherapy. Methods: Data was extracted from 147 patients with FIGO stage IA/IB, grade 2/3 or stage IC/IIA (any grade) who underwent primary surgery followed by paclitaxel/carboplatin chemotherapy. Results: Median follow-up was 88 months. Ten-year relapse-free (RFS) and disease-specific survival (DSS) were: 81% (95% confidence interval [CI]: 73-89) and 81% (95% CI: 73-89). On multivariate analysis, non serous histology was associated with reduced risk for RFS (0.294, 95% CI: 0.112-0.577, p = 0.001) and DSS (0.194, 95% CI: 0.075-0.504, p = 0.001), while high-risk category (stage IC/IIA and grade 2/3) with increased risk for RFS (3.989, 95% CI: 1.189-13.389, p = 0.009) and DSS (3.989, 95% CI: 1.064-16.386, p = 0.038). The combination of histology and grade identified 3 groups with distinctly different 10-year RFS and DSS rates (p &lt; 0.001): grade 1 (100% and 100%), non-serous grade 2/3 (83% and 86%) and serous grade 2/3 (60% and 60%). Conclusions: Serous histology is an adverse prognostic factor in early-stage ovarian cancer treated with adjuvant paclitaxel/carboplatin. Risk stratification according to histology and grade is a useful discriminator of prognosis and can be used in the design of future studies. © 2011 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">Cited By :8Export Date: 21 February 2017</style></notes></record></records></xml>